In the era of AI-driven discovery, the demand for high-fidelity models is urgent. At ADA 2026, we present the SDT fatty/Jcl rat as a premier platform for CKM drug evaluation. By mirroring human-like disease progression with clear pharmacological responsiveness, this model meets the rigorous standards of today’s leading scientists.
Our journey with the SDT fatty/Jcl began in 2016. In collaboration with Physiogenex S.A.S., we have expanded our expertise step-by-step—starting from DKD and Retinopathy to the current focus on heart failure with preserved ejection fraction (HFpEF) and beyond. This decade of longitudinal observation across various pharmacological scenarios has provided us with deep, practical insights into the model’s unique response patterns. At ADA 2026, we are excited to share this accumulated knowledge with the global research community.
Coming to ADA 2026: Beyond the 6-Week Horizon
Building on the 6-week findings from ISN 2026, we are ready to unveil the full 12-week study results at ADA this year. While our previous report focused on the initial suppression of hyperfiltration, our final data captures the model’s deeper pathological transition as it moves beyond the 6-week mark.
【ISN 2026 Poster】
- 6-week Interim results of Semaglutide.
- Key Insight: Early suppression of hyperfiltration and improved HFpEF.
Download Full Poster PDF (ISN 2026)
Is the convergence at 12 weeks a sign of stability?
At our poster session, we will present evidence of how the SDT fatty/Jcl mirrors the CKM progression observed in humans, and how benefits observed with Semaglutide in patients with the CKM syndrome.
Discover the full cardiorenal story and the long-term impact on HFpEF at Poster #2026-A-2831-Diabetes.
📅 June 6th | 12:30 PM – 1:30 PM
📍 Exhibit Hall (Level 1), Ernest N. Morial Convention Center
Strategic Reference Highlights: The Foundation of SDT fatty Research
[Cardiorenal Legacy]
Liraglutide Improves Both Diabetic Nephropathy and Cardiomyopathy in the SDT Fatty Rat, a Cardiorenal Model of Type 2 DiabetesBeneficial effects of SGLT2 inhibitor on metabolic inflexibility and visceral fat amount in animal model of obese type 2 diabetes
- One of the first studies to establish the SDT fatty/Jcl as a dual cardiorenal model.
- Demonstrates GLP-1RA effects on both kidney lesions and cardiac hypertrophy.
[High-Efficiency DKD Screening]
Salt loading with unilateral nephrectomy accelerates decline in glomerular filtration rate in the hypertensive, obese, type 2 diabetic SDT fatty rat model of diabetic kidney disease
- Introduces an accelerated GFR decline protocol within just 10 weeks.
- A vital reference for high-throughput advanced diabetic kidney disease research.
[Multi-Organ All-in-One]
Female spontaneously diabetic Torii fatty rats develop nonalcoholic steatohepatitis-like hepatic lesions
- The definitive study confirming multi-organ metabolic complications in the female model.
- Demonstrates the natural progression of NASH/MASH lesions alongside chronic diabetes.
Protective Effect of Pemafibrate Treatment against Diabetic Retinopathy in Spontaneously Diabetic Torii Fatty Rats
- A critical validation of the model’s utility for advanced diabetic microvascular research.
- Highlights the therapeutic responsiveness for retinopathy, beyond standard glucose control.
Endurance exercise training-attenuated diabetic kidney disease with muscle weakness in spontaneously diabetic Torii fatty rats
- The primary reference for metabolic sarcopenia, linking muscle weakness to kidney progression.
- Demonstrates how physical exercise mitigates systemic decline, making it ideal for frailty research.
Pathophysiological abnormalities in the brains of Spontaneous Diabetes Torii-Leprfa (SDT fatty) rats, a novel type 2 diabetic model.
- Reveals the model’s unique neuro-metabolic axis, including cognitive-related brain tissue changes.
- Establishes the rat as a dual-utility model for studying the interplay between T2D and neurodegeneration.
[Genetic Stability]
A novel model of obesity-related diabetes: introgression of the Lepr(fa) allele of the Zucker fatty rat into nonobese Spontaneously Diabetic Torii (SDT) rats
- The foundational paper proving 100% spontaneous onset of diabetes.
- Ensures the genetic and phenotypic consistency maintained for over 20 years.
Contact
Masataka Tsubaki
CLEA Japan, Inc. – SDT Fatty Program
Tsubaki-m@clea-japan.com
or
For collaboration, joint studies, or model access, please contact CLEA Japan and our partner CROs using the inquiry form below.
Confidential discussion available upon request.
